These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28199679)

  • 21. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
    Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
    Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques.
    Han Q; Williams WB; Saunders KO; Seaton KE; Wiehe KJ; Vandergrift N; Von Holle TA; Trama AM; Parks RJ; Luo K; Gurley TC; Kepler TB; Marshall DJ; Montefiori DC; Sutherland LL; Alam MS; Whitesides JF; Bowman CM; Permar SR; Graham BS; Mascola JR; Seed PC; Van Rompay KKA; Tomaras GD; Moody MA; Haynes BF
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
    Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
    PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
    Keefer MC; Gilmour J; Hayes P; Gill D; Kopycinski J; Cheeseman H; Cashin-Cox M; Naarding M; Clark L; Fernandez N; Bunce CA; Hay CM; Welsh S; Komaroff W; Hachaambwa L; Tarragona-Fiol T; Sayeed E; Zachariah D; Ackland J; Loughran K; Barin B; Cormier E; Cox JH; Fast P; Excler JL
    PLoS One; 2012; 7(8):e41936. PubMed ID: 22870265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.
    García-Arriaza J; Nájera JL; Gómez CE; Sorzano CO; Esteban M
    PLoS One; 2010 Aug; 5(8):e12395. PubMed ID: 20811493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.
    Koblin BA; Casapia M; Morgan C; Qin L; Wang ZM; Defawe OD; Baden L; Goepfert P; Tomaras GD; Montefiori DC; McElrath MJ; Saavedra L; Lau CY; Graham BS;
    PLoS One; 2011; 6(9):e24517. PubMed ID: 21931737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.
    Gómez CE; Perdiguero B; Falqui M; Marín MQ; Bécares M; Sorzano CÓS; García-Arriaza J; Esteban M; Guerra S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
    Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
    Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
    Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
    J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-Reactive CD8 T-Cell Responses Elicited by Adenovirus Type 5-Based HIV-1 Vaccines Contributed to Early Viral Evolution in Vaccine Recipients Who Became Infected.
    Boppana S; Fiore-Gartland A; Bansal A; Goepfert P
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31645444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
    Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
    PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.
    Perdiguero B; Raman SC; Sánchez-Corzo C; Sorzano COS; Valverde JR; Esteban M; Gómez CE
    Viruses; 2018 Aug; 10(8):. PubMed ID: 30104537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.
    Casazza JP; Bowman KA; Adzaku S; Smith EC; Enama ME; Bailer RT; Price DA; Gostick E; Gordon IJ; Ambrozak DR; Nason MC; Roederer M; Andrews CA; Maldarelli FM; Wiegand A; Kearney MF; Persaud D; Ziemniak C; Gottardo R; Ledgerwood JE; Graham BS; Koup RA;
    J Infect Dis; 2013 Jun; 207(12):1829-40. PubMed ID: 23482645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.
    Auclair S; Liu F; Niu Q; Hou W; Churchyard G; Morgan C; Frahm N; Nitayaphan S; Pitisuthithum P; Rerks-Ngarm S; Kimata JT; Soong L; Franchini G; Robb M; Kim J; Michael N; Hu H
    PLoS Pathog; 2018 Feb; 14(2):e1006888. PubMed ID: 29474461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16).
    Launay O; Surenaud M; Desaint C; Ben Hamouda N; Pialoux G; Bonnet B; Poizot-Martin I; Gonzales G; Cuzin L; Bourgault-Villada I; Lévy Y; Choppin J; Durier C
    Vaccine; 2013 Sep; 31(40):4406-15. PubMed ID: 23850610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
    Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.
    de Souza MS; Ratto-Kim S; Chuenarom W; Schuetz A; Chantakulkij S; Nuntapinit B; Valencia-Micolta A; Thelian D; Nitayaphan S; Pitisuttithum P; Paris RM; Kaewkungwal J; Michael NL; Rerks-Ngarm S; Mathieson B; Marovich M; Currier JR; Kim JH;
    J Immunol; 2012 May; 188(10):5166-76. PubMed ID: 22529301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
    Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
    J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.
    Kalams SA; Parker SD; Elizaga M; Metch B; Edupuganti S; Hural J; De Rosa S; Carter DK; Rybczyk K; Frank I; Fuchs J; Koblin B; Kim DH; Joseph P; Keefer MC; Baden LR; Eldridge J; Boyer J; Sherwat A; Cardinali M; Allen M; Pensiero M; Butler C; Khan AS; Yan J; Sardesai NY; Kublin JG; Weiner DB;
    J Infect Dis; 2013 Sep; 208(5):818-29. PubMed ID: 23840043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.